The second most cited article globally is Ansell SM’s ‘PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma’, published in the New England Journal of Medicine in 2015. The gene discussed is RPL17; the disease is Hodgkins lymphoma.